Use of bacteriophages as an alternative in the control of bacterial infections

Detalhes bibliográficos
Autor(a) principal: Silva, Líllian Oliveira Pereira da
Data de Publicação: 2022
Outros Autores: Nogueira, Joseli Maria da Rocha
Tipo de documento: Artigo
Idioma: por
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/33619
Resumo: WHO predicts that, by 2050, infections caused by resistant bacteria will cause about 10 million deaths annually. Considered a public health crisis neglected worldwide, bacterial resistance (AMR) has been aggravated by the indiscriminate use of antimicrobials, which can be transmitted from one organism to another, favoring the emergence of pan-resistant bacteria. From this scenario, it is necessary to search for alternative treatment methodologies, such as phage therapy, which is based on the use of the natural replication mechanism of bacteriophages to cause bacterial cell lysis, which can be an excellent option for the treatment and control of infections caused by resistant bacteria. Therefore, this work aimed to highlight the potential of phage therapy in the fight against such infections, where this technique has shown positive and hopeful results in the fight against infections in several sites and by different routes of administration, even allowing the treatment of infections caused by biofilm-producing bacteria. It is, therefore, an extremely advantageous technique, using extremely specific viruses regarding the target microorganism, which ends up reducing the risks of toxicity, allergic reactions and dysbiosis. In addition, the combined use of bacteriophages and antibiotics presents synergistic results that allow the reduction of the antimicrobial loading dose and a greater effectiveness in the treatment. However, as phage therapy still does not have specific protocols for its use, further studies related to its implementation are needed, so that it is possible to enjoy this alternative treatment more in the future.
id UNIFEI_f4fbe686ab6367f4bcf22ee194e7d94f
oai_identifier_str oai:ojs.pkp.sfu.ca:article/33619
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Use of bacteriophages as an alternative in the control of bacterial infectionsUso de bacteriófagos como alternativa en el control de infecciones bacterianasUso de bacteriófagos como alternativa no controle de infecções bacterianasActividad antibacterialBacteriófagosFagoterapiaResistencia bacteriana.Antibacterial activityPhagotherapyBacteriophagesBacterial resistance.Atividade antibacterianaFagoterapiaBacteriófagosResistência bacteriana.WHO predicts that, by 2050, infections caused by resistant bacteria will cause about 10 million deaths annually. Considered a public health crisis neglected worldwide, bacterial resistance (AMR) has been aggravated by the indiscriminate use of antimicrobials, which can be transmitted from one organism to another, favoring the emergence of pan-resistant bacteria. From this scenario, it is necessary to search for alternative treatment methodologies, such as phage therapy, which is based on the use of the natural replication mechanism of bacteriophages to cause bacterial cell lysis, which can be an excellent option for the treatment and control of infections caused by resistant bacteria. Therefore, this work aimed to highlight the potential of phage therapy in the fight against such infections, where this technique has shown positive and hopeful results in the fight against infections in several sites and by different routes of administration, even allowing the treatment of infections caused by biofilm-producing bacteria. It is, therefore, an extremely advantageous technique, using extremely specific viruses regarding the target microorganism, which ends up reducing the risks of toxicity, allergic reactions and dysbiosis. In addition, the combined use of bacteriophages and antibiotics presents synergistic results that allow the reduction of the antimicrobial loading dose and a greater effectiveness in the treatment. However, as phage therapy still does not have specific protocols for its use, further studies related to its implementation are needed, so that it is possible to enjoy this alternative treatment more in the future.La OMS predice que, para 2050, las infecciones causadas por bacterias resistentes causarán alrededor de 10 millones de muertes al año. Considerada una crisis mundial de salud pública desatendida, la resistencia bacteriana (RAM) se ha visto agravada por el uso indiscriminado de antimicrobianos, los cuales pueden transmitirse de un organismo a otro, favoreciendo la aparición de bacterias panrresistentes. A partir de este escenario, es necesario buscar metodologías alternativas de tratamiento, como la fagoterapia, que se basa en el uso del mecanismo de replicación natural de los bacteriófagos para provocar la lisis de las células bacterianas, que puede ser una excelente opción para el tratamiento y control de Infecciones causadas por bacterias resistentes. Por lo tanto, este trabajo tuvo como objetivo resaltar el potencial de la fagoterapia en la lucha contra este tipo de infecciones, donde esta técnica ha mostrado resultados positivos y esperanzadores en la lucha contra infecciones en varios sitios y por diferentes vías de administración, permitiendo incluso el tratamiento de infecciones causadas por bacterias productoras de biopelículas. Se trata, por tanto, de una técnica extremadamente ventajosa, utilizando virus extremadamente específicos respecto al microorganismo diana, lo que acaba reduciendo los riesgos de toxicidad, reacciones alérgicas y disbiosis. Además, el uso combinado de bacteriófagos y antibióticos presenta resultados sinérgicos que permiten la reducción de la dosis de carga antimicrobiana y una mayor efectividad en el tratamiento. Sin embargo, como la fagoterapia aún no cuenta con protocolos específicos para su uso, se necesitan más estudios relacionados con su implementación, de modo que se pueda disfrutar más de esta alternativa de tratamiento en el futuro.A OMS prevê que, até 2050, infecções causadas por bactérias resistentes causarão cerca de 10 milhões mortes anuais. Considerada uma crise de saúde pública negligenciada mundialmente, a resistência bacteriana (AMR) vem sendo agravada pelo uso indiscriminado dos antimicrobianos, podendo ser transmitida de um organismo ao outro, favorecendo o surgimento de bactérias pan-resistentes. A partir desse cenário, é necessária a busca de metodologias alternativas de tratamento, como a fagoterapia, que é baseada na utilização do mecanismo de replicação natural dos bacteriófagos para causar a lise da célula bacteriana, o que pode ser uma excelente opção para o tratamento e controle de infecções causadas pelas bactérias resistentes. Sendo assim, este trabalho teve como objetivo destacar o potencial da fagoterapia no combate de tais infecções, onde tal técnica vem apresentando resultados positivos e esperançosos no combate de infecções em diversos sítios e por diferentes vias de administração, possibilitando até mesmo o tratamento de infecções causadas por bactérias produtoras de biofilme. Trata-se, portanto, de uma técnica extremamente vantajosa, utilizando vírus extremamente específicos quanto ao microrganismo alvo, o que acaba por diminuir os riscos de toxicidade, reações alérgicas e disbioses. Além disso, o uso combinado de bacteriófagos e antibióticos apresenta resultados sinérgicos que possibilitam a redução da dose de ataque dos antimicrobianos e uma maior eficácia no tratamento. Contudo, como a fagoterapia ainda não apresenta protocolos específicos para seu uso, são necessários maiores estudos relacionados à sua implementação, para que seja possível desfrutar de mais essa alternativa de tratamento no futuro.Research, Society and Development2022-08-20info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/3361910.33448/rsd-v11i11.33619Research, Society and Development; Vol. 11 No. 11; e200111133619Research, Society and Development; Vol. 11 Núm. 11; e200111133619Research, Society and Development; v. 11 n. 11; e2001111336192525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/33619/28345Copyright (c) 2022 Líllian Oliveira Pereira da Silva; Joseli Maria da Rocha Nogueirahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessSilva, Líllian Oliveira Pereira da Nogueira, Joseli Maria da Rocha 2022-09-05T13:24:46Zoai:ojs.pkp.sfu.ca:article/33619Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:49:12.872374Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Use of bacteriophages as an alternative in the control of bacterial infections
Uso de bacteriófagos como alternativa en el control de infecciones bacterianas
Uso de bacteriófagos como alternativa no controle de infecções bacterianas
title Use of bacteriophages as an alternative in the control of bacterial infections
spellingShingle Use of bacteriophages as an alternative in the control of bacterial infections
Silva, Líllian Oliveira Pereira da
Actividad antibacterial
Bacteriófagos
Fagoterapia
Resistencia bacteriana.
Antibacterial activity
Phagotherapy
Bacteriophages
Bacterial resistance.
Atividade antibacteriana
Fagoterapia
Bacteriófagos
Resistência bacteriana.
title_short Use of bacteriophages as an alternative in the control of bacterial infections
title_full Use of bacteriophages as an alternative in the control of bacterial infections
title_fullStr Use of bacteriophages as an alternative in the control of bacterial infections
title_full_unstemmed Use of bacteriophages as an alternative in the control of bacterial infections
title_sort Use of bacteriophages as an alternative in the control of bacterial infections
author Silva, Líllian Oliveira Pereira da
author_facet Silva, Líllian Oliveira Pereira da
Nogueira, Joseli Maria da Rocha
author_role author
author2 Nogueira, Joseli Maria da Rocha
author2_role author
dc.contributor.author.fl_str_mv Silva, Líllian Oliveira Pereira da
Nogueira, Joseli Maria da Rocha
dc.subject.por.fl_str_mv Actividad antibacterial
Bacteriófagos
Fagoterapia
Resistencia bacteriana.
Antibacterial activity
Phagotherapy
Bacteriophages
Bacterial resistance.
Atividade antibacteriana
Fagoterapia
Bacteriófagos
Resistência bacteriana.
topic Actividad antibacterial
Bacteriófagos
Fagoterapia
Resistencia bacteriana.
Antibacterial activity
Phagotherapy
Bacteriophages
Bacterial resistance.
Atividade antibacteriana
Fagoterapia
Bacteriófagos
Resistência bacteriana.
description WHO predicts that, by 2050, infections caused by resistant bacteria will cause about 10 million deaths annually. Considered a public health crisis neglected worldwide, bacterial resistance (AMR) has been aggravated by the indiscriminate use of antimicrobials, which can be transmitted from one organism to another, favoring the emergence of pan-resistant bacteria. From this scenario, it is necessary to search for alternative treatment methodologies, such as phage therapy, which is based on the use of the natural replication mechanism of bacteriophages to cause bacterial cell lysis, which can be an excellent option for the treatment and control of infections caused by resistant bacteria. Therefore, this work aimed to highlight the potential of phage therapy in the fight against such infections, where this technique has shown positive and hopeful results in the fight against infections in several sites and by different routes of administration, even allowing the treatment of infections caused by biofilm-producing bacteria. It is, therefore, an extremely advantageous technique, using extremely specific viruses regarding the target microorganism, which ends up reducing the risks of toxicity, allergic reactions and dysbiosis. In addition, the combined use of bacteriophages and antibiotics presents synergistic results that allow the reduction of the antimicrobial loading dose and a greater effectiveness in the treatment. However, as phage therapy still does not have specific protocols for its use, further studies related to its implementation are needed, so that it is possible to enjoy this alternative treatment more in the future.
publishDate 2022
dc.date.none.fl_str_mv 2022-08-20
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/33619
10.33448/rsd-v11i11.33619
url https://rsdjournal.org/index.php/rsd/article/view/33619
identifier_str_mv 10.33448/rsd-v11i11.33619
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/33619/28345
dc.rights.driver.fl_str_mv Copyright (c) 2022 Líllian Oliveira Pereira da Silva; Joseli Maria da Rocha Nogueira
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2022 Líllian Oliveira Pereira da Silva; Joseli Maria da Rocha Nogueira
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 11 No. 11; e200111133619
Research, Society and Development; Vol. 11 Núm. 11; e200111133619
Research, Society and Development; v. 11 n. 11; e200111133619
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052797541154816

Registros relacionados